SMART CELLS FOR LIFE
LIVE

Serial Number

79311713

Owner

Tigen Pharma SA

Attorney

Stacey Halpern

Filing Date

Feb 4, 2021

Add to watchlist:

No watchlists yet
View on USPTO

SMART CELLS FOR LIFE Trademark

Serial Number: 79311713 • Registration: 6784096

SMART CELLS FOR LIFE is a trademark filed by Tigen Pharma SA on February 4, 2021. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Tigen Pharma SA (3 trademarks)

voie du Chariot 3

Entity Type: 33

Trademark Details

Filing Date

February 4, 2021

Registration Date

July 12, 2022

Published for Opposition

April 26, 2022

Goods & Services

Pharmaceutical products and medical preparations, namely, gene-modified and non-gene-modified cellular therapies for the treatment of localized and systemic malignant hematological and oncological diseases, genetic diseases, autoimmune diseases and infectious diseases; none of the foregoing being dietary and nutritional supplement or skin care products

Chemical, biochemical, biological and biotechnological preparations, namely, polypeptides and proteins, for use in industry and science; chemical, biochemical, biological and biotechnological preparations, namely, polypeptides and proteins, for use in the development being the manufacture, and manufacture of reagents for industrial or scientific use; chemical, biochemical, biological and biotechnological preparations, namely, polypeptides or proteins, for use of laboratories, diagnostics and analyses for industrial or scientific use; chemical, biochemical, biological and biotechnological substances, namely, polypeptides and proteins, for use in the manufacture of pharmaceuticals; none of the foregoing being silicon and semiconductor materials or chemical compounds in the nature of Gallium arsenide, Indium phosphide, Indium gallium arsenide, Indium gallium arsenide phosphide, for the production of enzyme substrates in the field of microelectronics and none of the foregoing being dietary and nutritional supplement or skin care products

Medical services; pharmacy advice services, namely, pharmaceutical consultation; medical clinic services provided by medical laboratories for diagnostic purposes; preparation and dispensing of medication; preparation of prescriptions by pharmacists; none of the foregoing being dietary and nutritional supplement or skin care products

Medical instruments, equipment and apparatus, namely, instruments, equipment and apparatus for cell and cell material collection, thawing, washing, selection, expansion, modification, harvesting, final formulation, freezing, storage and infusion into a patient in the fields of genetic diseases, autoimmune diseases, infectious diseases, localized and systemic malignant hematological and oncological diseases and other cell and cell-material based diseases and conditions; none of the foregoing being dietary and nutritional supplement or skin care products

Scientific research, technological development of new products for third parties; medical research; scientific and industrial research in biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious and tumor diseases; research in the field of biomedical and phytopharmaceutical technology; scientific laboratory services; pharmaceutical research and development services; scientific services, namely, development of medicines, active substances and vaccines; design and development of computer hardware and software for use in medical and scientific research and in the development of new products, in research and development of new products in the field of biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases; upgrading, maintenance and rental of computer software; updating, maintenance and rental of computer software for use in medical and scientific research and in the development of new products, in research and development of new products in the field of biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases; software as a service (SaaS) services featuring software for controlling end-to-end process development, manufacturing, quality, and supply chain steps and featuring artificial intelligence search engine software to be used in medical and scientific research and in the development of new products in research and development of new products in the field of biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases; chemical and biological laboratory services; none of the foregoing being dietary and nutritional supplement or skin care products

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Dec 31, 2023 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 14, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 21, 2022 FICS
FINAL DISPOSITION PROCESSED
Oct 21, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 12, 2022 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 12, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 12, 2022 R.PR
NOTIFICATION PROCESSED BY IB
May 3, 2022 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 26, 2022 NPUB
PUBLISHED FOR OPPOSITION
Apr 26, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 13, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 13, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 6, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 24, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 24, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 24, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 24, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 24, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 15, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 14, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 14, 2022 TROA
REFUSAL PROCESSED BY IB
Oct 4, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 14, 2021 RFCS
REFUSAL PROCESSED BY MPU
Sep 14, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 14, 2021 RFCR
NON-FINAL ACTION WRITTEN
Sep 13, 2021 CNRT
ASSIGNED TO EXAMINER
Aug 27, 2021 DOCK
NEW REPRESENTATIVE AT IB RECEIVED
Aug 27, 2021 NREP
APPLICATION FILING RECEIPT MAILED
Jun 5, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 1, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 27, 2021 REPR